Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Pembrolizumab in Stage III NSCLC
NCT02343952Phase 2Completed
- Start
- Mar 2015
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Time to Death or Distant Metastasis up to 47 months. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02343952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343952.